Patent ID: 11965176
Assignee: HUNAN SIWEIKANG THERAPEUTICS CO. LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC C

Claim 0:
1. A population of immune cells, comprising:
a plurality of modified immune cells, which (a) produces a reduced level of one or more inflammatory proteins as compared with wild-type immune cells of the same type under the same conditions; and
(b) expresses one or more antagonists of the one or more inflammatory proteins and/or expresses one or more immune suppressive cytokines,
wherein the one or more inflammatory proteins in (a) comprise GM-CSF, IL2, TNF, or a combination thereof;
wherein the one or more antagonists in (b) comprise IL-1RA or an antibody selected from the group consisting of tocilizumab, sirukumab, sarilumab, siltuximab, olokizumab, clazakizumab, or an antigen-binding fragment thereof, or a combination thereof;
wherein the one or more immune suppressive cytokines in (b) comprise TGFβ, IL-4, IL-10, IL-13, IL-33, IL-35, or IL-37; and
wherein the plurality of modified immune cells comprises T cells.